Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetraethylammonium is a quaternary ammonium cation and experimental drug primarily used as a pharmacological research agent. Its main mechanism of action is the blockade of voltage-gated potassium channels, both calcium and voltage activated, as well as inhibition at autonomic ganglia and antagonism at nicotinic acetylcholine receptors. Tetraethylammonium was historically investigated for clinical use as a vasodilator and ganglionic blocker but was discontinued due to serious toxic effects and inconsistent cardiovascular responses. It is not orally active in humans. Today, it is mainly used in research settings to study ion channel physiology or as a reagent in chemical synthesis[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetraethylammonium.